Faculty

Dr. Greg Piazza is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He is also the Director of the Vascular Medicine Section at Brigham and Women’s Hospital. Dr. Piazza received his medical degree from the University of Massachusetts in Worcester, Massachusetts. He completed his residency in Internal Medicine and his fellowship in General Cardiology at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He also completed a fellowship at the National Heart, Lung, and Blood Institute in Vascular Medicine at Brigham and Women’s Hospital. Dr. Piazza is board-certified in Cardiovascular Disease by the American Board of Internal Medicine and in Vascular Medicine by the American Board of Vascular Medicine.

Dr. Piazza’s research interests include epidemiology, pathophysiology, diagnosis, treatment, and prevention of arterial and venous thromboembolism, thrombophilia-associated infertility, and computerized decision support to improve cardiovascular outcomes.

Dr. Piazza is a member of several professional societies, including the American Medical Association, the American College of Physicians, the American Heart Association, the American College of Cardiology, the American College of Chest Physicians, the Society for Vascular Biology, and the Vascular Interventional Advances Physicians.

Dr. Piazza received the BWH Department of Medicine Award for Exemplary Service in 2023. He was also a nominee for the Department of Medicine Kenneth L. Baughman Mentoring Award. In 2015, he received the Excellence in Ambulatory Lecturing Award. He has also received various other awards & honors throughout his career.

Dr. Greg Piazza discloses he is involved with grants from Bristol-Myers Squibb/Pfizer Alliance, Bayer, Janssen, Alexion, Regeneron, Experion, Amgen, and Boston Scientific Corporation. He also discloses that he is an advisor for Bristol-Myers Squibb/Pfizer Alliance, Boston Scientific Corporation, Janssen, NAMSA, Penumbra, and Thrombole. All relevant financial relationships have been mitigated.